Odyssean LLC Invests $3.06 Million in BridgeBio Pharma, Inc. $BBIO

Odyssean LLC acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the second quarter, HoldingsChannel reports. The firm acquired 41,015 shares of the company’s stock, valued at approximately $3,055,000.

Other large investors have also modified their holdings of the company. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma in the first quarter worth $35,000. First Trust Advisors LP increased its holdings in BridgeBio Pharma by 200.4% in the 2nd quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock valued at $11,386,000 after buying an additional 175,918 shares during the period. Baird Financial Group Inc. raised its stake in shares of BridgeBio Pharma by 1.8% in the 2nd quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock valued at $1,816,000 after buying an additional 731 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of BridgeBio Pharma in the 2nd quarter valued at $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of BridgeBio Pharma by 2.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock worth $4,132,000 after acquiring an additional 2,206 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target, indicating that the analyst believes BridgeBio’s longer-term growth potential remains intact despite the earnings-estimate reductions. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma
• Positive Sentiment: Barclays and Cantor Fitzgerald also maintained Buy ratings on BridgeBio Pharma, providing additional analyst support for the stock. Barclays Sticks to Its Buy Rating for BridgeBio Pharma Cantor Fitzgerald Remains a Buy on BridgeBio Pharma
• Neutral Sentiment: HC Wainwright’s estimates still imply a transition from losses in 2026 to profitability in 2027, forecasting a $1.88 per-share loss for fiscal 2026 and $1.31 in earnings for fiscal 2027.
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 EPS forecast to a $1.88 loss from a $1.50 loss and cut its fiscal 2027 estimate to $1.31 from $2.19. It also reduced estimates for several 2027 quarters, including Q1 to a $0.18 loss from $0.11 in earnings and Q2 to $0.19 in earnings from $0.44.
• Negative Sentiment: The estimate cuts extend to near-term results: Q3 2026 EPS was lowered to a $0.40 loss from a $0.38 loss, while Q4 2026 EPS was trimmed slightly to $0.13 from $0.14. These revisions may weigh on sentiment because they point to slower-than-previously-expected earnings progression.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $74.84 on Friday. The company’s fifty day moving average is $80.74 and its 200-day moving average is $73.62. BridgeBio Pharma, Inc. has a 52 week low of $48.78 and a 52 week high of $93.42. The company has a market capitalization of $14.63 billion, a PE ratio of -20.96 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million for the quarter, compared to analyst estimates of $220.91 million. During the same period in the prior year, the business earned ($0.95) EPS. The firm’s quarterly revenue was up 120.4% compared to the same quarter last year. On average, analysts forecast that BridgeBio Pharma, Inc. will post -2.64 EPS for the current year.

Insider Activity

In other news, Director Hannah Valantine sold 2,196 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total value of $150,579.72. Following the completion of the transaction, the director owned 9,259 shares in the company, valued at approximately $634,889.63. The trade was a 19.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the transaction, the chief accounting officer directly owned 127,401 shares in the company, valued at $10,199,724.06. The trade was a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 347,343 shares of company stock valued at $27,591,000. Corporate insiders own 14.23% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BBIO shares. Canaccord Genuity Group lifted their target price on shares of BridgeBio Pharma from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of BridgeBio Pharma in a research report on Wednesday. Bank of America raised their price target on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Piper Sandler lifted their price objective on BridgeBio Pharma from $111.00 to $115.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. upped their price objective on BridgeBio Pharma from $100.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Twenty research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $101.53.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.